Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower

Moving up:
  • Pacific Ethanol PEIX - up 29% - reports Q4 EPS of $0.54 vs $(0.04) analyst estimates. Revenue came in at $215.30M.
  • JC Penney JCP - up 22% - EPS of $0.11 vs $(0.76) Est; Revenue of $3.78B vs $3.94B Est; Upgraded by Wells Fargo from Underperform to Market Perform.
  • Synthesis Energy SYMX - up 20% - Premarket on Twitter Mention of Possible GE Cooperation.
  • Cobalt International Energy CIE - up 9.5% - Reports Q4 loss of $0.21 per share, excluding non-recurring items versus analyst estimates of ($0.15).
  • Cell Therapeutics CTIC - up 8.2% - NICE publishes final guidance on PIXUVRI (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
  • Cardica CRDC - up 8% - Receives FDA 510(k) Clearance for Both MicroCutter XCHANGE™ 30 White Cartridge And New Material.
  • Sears SHLD - up 7.5% - Reports Q4 EPS of $(3.37) vs $(1.14) Est; Revenue of $10.59B vs $9.0B Est.
  • Best Buy BBY - up 7.2% - Reports Q4 EPS of $1.24 vs $1.01 Est; Revenue of $14.50B vs $14.66B Est.
  • Solazyme SZYM - up 6% - Reports Q4 EPS of $(0.49) vs $(0.39) Est; Revenue of $11.30M vs $12.11M Est.
  • Workday WDAY - up 5.5% - Reports Q4 EPS of $(0.32) vs $(0.16) Est; Revenue of $141.90M vs $137.91M Est.
  • Cimatron CIMT - up 3.5% - Reports revenue of $12.7M vs $12.6M estimates; Reported EPS of $0.16, missing analyst estimates of $0.18.
Moving down:
  • Inovio Pharmaceuticals INO - down 12% - Announces Public Offering of Common Stock; Size Not Mentioned.
  • Noodles & Company NDLS - down 6.5% - Reports Q4 EPS of $0.11 vs $0.12 Est; Revenue of $91.5M vs $92.5M Est.
  • Halcon Resources HK - down 5.7% - Reports Q4 EPS of $0.01 vs $0.04 Est; Revenue of $289.30M vs $290.09M Est.
  • Cypress Semiconductor CY - down 4.5% - Downgraded by Pacific Crest from Outperform to Sector Perform and removes the price target of $11.
  • Dyax Corp DYAX - down 2.8% - Leerink Swann Downgrades Dyax Corp. to Market Perform, Maintains $12.00 PT.
  • Exact Sciences EXAS - down 2.5% - Will present its case before an FDA panel of experts on March 27; Cologuard CRC test is expected to be cleared by the FDA this year (via Seeking Alpha).
  • Wabash National WNC - down 2.5% - Morgan Stanley Initiates Coverage on Wabash National Corporation at Underweight.
  • Walter Investment Management WAC - down 2.5% - Reports Q4 EPS of $1.07 vs $1.24 Est; Revenue of $402.80M vs $396.22M Est. Lowers FY2014 EPS Guidance from $6.00-6.50 to $5.25-6.25 vs $5.82 Est.
  • BioScrip BIOS - down 2.5% - Reports Q4 EPS of $(0.23) vs $0.02 Est; Revenue of $243.50M vs $237.58M Est.
  • Zogenix ZGNX - down 1.5% - Pressure grows on FDA to revoke approval of Zogenix's Zohydro (via Seeking Alpha)
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!